The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Here are the best ways to treat and prevent motion sickness while traveling. Browse treatments from brands like Dramamine, ...

Around 92% of people living in the UK have used at least one over-the-counter drug in the past year. While these drugs make ...

CRAIG T. KOJIMA / NOV. 6 The judge instructed jurors Wednesday that they were allowed to find babysitter Dixie Denise Villa ...